SAN DIEGO—(BUSINESS WIRE)—Dec. 15, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system disorders,today announced Julian C. Baker has joined its Board of Directors.
“After more than 20 years as a professional investor, Julian hasextensive experience in financing and building companies in the lifesciences industry,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’sBoard of Directors. “We welcome Julian to our board and look forward tohis insights as we advance NUPLAZID™ through registration forParkinson’s disease psychosis and position ACADIA for strong growth.”
Mr. Baker is a Managing Partner at Baker Brothers Investments, whichmanages long-term investment funds focused on publicly traded lifesciences companies, for major university endowments and foundations. Mr.Baker and his brother Felix Baker, Ph.D., founded the firm in 2000. Mr.Baker’s career as a fund manager began in 1994 when he co-founded abiotechnology investing partnership with the Tisch family. Mr. Bakercurrently serves on the board of directors of Incyte Corporation,Genomic Health, Inc., and Idera Pharmaceuticals, Inc. Mr. Baker holds anA.B. Magna Cum Laude from Harvard University.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the potential for NUPLAZID(pimavanserin) to be the first drug approved in the United States forParkinson’s disease psychosis (PDP) and the potential timing of suchapproval, if approved at all, by the FDA; the benefits to ACADIA of Mr.Baker joining its Board of Directors; the progress, timing and resultsof ACADIA’s drug discovery and development programs, either alone orwith a partner, including the progress and expected timing of clinicaltrials; and the benefits to be derived from ACADIA’s product candidates,including pimavanserin. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and collaborations with others, and thefact that past results of clinical trials and past regulatory decisionsmay not be indicative of future trial results or future regulatorydecisions, respectively. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2014 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director ofInvestor Relations
858-558-2871